The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Takeda Pharmaceutical Company Limited (TAK) Stock:...

Takeda Pharmaceutical Company Limited (TAK) Stock: Tracking the Weekly Performance

The stock of Takeda Pharmaceutical Company Limited (TAK) has seen a 3.10% increase in the past week, with a 8.31% gain in the past month, and a 1.18% flourish in the past quarter. The volatility ratio for the week is 0.60%, and the volatility levels for the past 30 days are at 0.73% for TAK. The simple moving average for the last 20 days is 5.30% for TAK’s stock, with a simple moving average of 2.91% for the last 200 days.

Is It Worth Investing in Takeda Pharmaceutical Company Limited (NYSE: TAK) Right Now?

Takeda Pharmaceutical Company Limited (NYSE: TAK) has a higher price-to-earnings ratio of 25.04x compared to its average ratio, and the 36-month beta value for TAK is at 0.63. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 11 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price suggested by analysts for TAK is $16.36, which is $2.57 above the current market price. The public float for TAK is 3.16B, and currently, shorts hold a 0.20% of that float. The average trading volume for TAK on September 20, 2023 was 2.12M shares.

TAK) stock’s latest price update

Takeda Pharmaceutical Company Limited (NYSE: TAK)’s stock price has dropped by -0.06 in relation to previous closing price of 16.31. Nevertheless, the company has seen a gain of 3.10% in its stock price over the last five trading days. Reuters reported 2023-08-31 that Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical’s drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

Analysts’ Opinion of TAK

Many brokerage firms have already submitted their reports for TAK stocks, with BofA Securities repeating the rating for TAK by listing it as a “Buy.” The predicted price for TAK in the upcoming period, according to BofA Securities is $20 based on the research report published on March 16, 2023 of the current year 2023.

TAK Trading at 5.87% from the 50-Day Moving Average

After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.96% of loss for the given period.

Volatility was left at 0.73%, however, over the last 30 days, the volatility rate increased by 0.60%, as shares surge +8.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.89% upper at present.

During the last 5 trading sessions, TAK rose by +3.10%, which changed the moving average for the period of 200-days by +10.66% in comparison to the 20-day moving average, which settled at $15.54. In addition, Takeda Pharmaceutical Company Limited saw 4.49% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for TAK

Current profitability levels for the company are sitting at:

  • +16.34 for the present operating margin
  • +57.07 for the gross margin

The net margin for Takeda Pharmaceutical Company Limited stands at +7.87. The total capital return value is set at 6.06, while invested capital returns managed to touch 3.01. Equity return is now at value 4.60, with 2.10 for asset returns.

Based on Takeda Pharmaceutical Company Limited (TAK), the company’s capital structure generated 76.51 points at debt to equity in total, while total debt to capital is 43.35. Total debt to assets is 34.83, with long-term debt to equity ratio resting at 70.23. Finally, the long-term debt to capital ratio is 39.79.

When we switch over and look at the enterprise to sales, we see a ratio of 2.89, with the company’s debt to enterprise value settled at 0.44. The receivables turnover for the company is 5.73 and the total asset turnover is 0.30. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.


In conclusion, Takeda Pharmaceutical Company Limited (TAK) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.